A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial
Tekijät: Pirkko-Liisa Kellokumpu-Lehtinen, Timo Marttila, Antti Jekunen, Petteri Hervonen, Katariina Klintrup, Vesa Kataja, Tapio Utriainen, Marjaana Luukkaa, Markku Leskinen, Kalevi Pulkkanen, Anna-Liisa Kautio, Teppo Huttunen
Kustantaja: INT INST ANTICANCER RESEARCH
Julkaisuvuosi: 2020
Journal: Anticancer Research
Tietokannassa oleva lehden nimi: ANTICANCER RESEARCH
Lehden akronyymi: ANTICANCER RES
Vuosikerta: 40
Numero: 12
Aloitussivu: 6915
Lopetussivu: 6921
Sivujen määrä: 7
ISSN: 0250-7005
eISSN: 1791-7530
DOI: https://doi.org/10.21873/anticanres.14715
Verkko-osoite: https://ar.iiarjournals.org/content/40/12/6915
Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Patients and Methods: Altogether, 60 patients received CBZ 16 mg/m2 i.v. on day 1 and day 14 of a 4-week cycle. The mean serum PSA levels were 305 ng/ml, and the mean age 67 years. The primary endpoint was safety according to CTCAEv4.0. Results: A total of 255 4-week cycles of CBZ were administered. The most common grade 3/4 adverse events were neutropenia (16.7%), pain (13.3%), fatigue (10.0%), anemia (5.0%) and non-neutropenic infection (10.0%). PSA responses occurred in 10 patients (16.7%). Clinical benefit rate was 38.3% and median survival 10 months. Conclusion: Biweekly CBZ is a well-tolerated treatment resulting in meaningful benefits for heavily pretreated mCRPC patients.
